Pharmacodynamics studies. Data presented among patients treated with PANO/TAC/SIR (squares) compared with control patients (circles) treated with TAC/SIR only. (A) Immune cell populations (CD4, T cells, B cells, CD8, natural killer cells, monocytes, and T-regs) were measured by flow cytometry on days 28 (± 3) and 90 (± 3). (B) Histone 3 acetylation on lymphocyte subsets (CD8⁺, CD4⁺, and T-regs) on days 15 (±3) and 28 (±3). (C) IFN plasma, IL-10, and IL-6 levels on day 90 (±15). (D) GVHD biomarkers elafin, REG-3α, and ST2 on day 28 (±3). NK, natural killer.